Basilea Announces Agreement with BARDA for Development of Novel Antibacterial

Collaboration Will Accelerate Development of ISA247, a Promising New Antibacterial for Serious Infections

Basel, Switzerland, November 21, 2022 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a research and development agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the development of ISA247, a novel antibacterial agent.

About ISA247

ISA247 is a broad-spectrum antibacterial with activity against Gram-negative and Gram-positive bacteria, including multidrug-resistant strains. It has demonstrated potent activity against priority pathogens identified by the World Health Organization (WHO), including Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae.

ISA247 is currently in Phase 2 clinical development for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) caused by Gram-negative bacteria.

BARDA Collaboration

Under the terms of the agreement, BARDA will provide up to $92.2 million in funding to support the research and development of ISA247. This includes funding for clinical trials, manufacturing scale-up, and regulatory activities.

The collaboration with BARDA will enable Basilea to accelerate the development of ISA247 and bring it to patients in need as soon as possible.

Quotes

"We are delighted to announce this collaboration with BARDA, which will significantly advance the development of ISA247," said David Veitch, CEO of Basilea. "ISA247 has the potential to be a valuable new tool in the fight against serious bacterial infections, and we are committed to bringing it to patients as quickly as possible."

"BARDA is committed to supporting the development of innovative antibacterial agents to address the growing threat of antimicrobial resistance," said Dr. Gary Disbrow, Director of BARDA. "We are pleased to collaborate with Basilea on the development of ISA247, which has shown promise in preclinical and early clinical studies."